Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization

Acta Ophthalmologica

Volumn 89, Issue 3, 2011, Pages 218-221

  Stergiou, Panos K ^a   Symeonidis, Chrysanthos ^a   Dimitrakos, Stavros A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

intravitreal bevacizumab; proliferative diabetic retinopathy; retinal neovascularization; vascular leakage

Indexed keywords

BEVACIZUMAB;

ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RETINA NEOVASCULARIZATION; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL SYSTEM EXAMINATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CAPILLARY PERMEABILITY; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECURRENCE; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79954996148     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01669.x     Document Type: Article

References (21)

1. Aiello LP, Avery RL, Arrigg PG, et al., (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487. (Pubitemid 24356306)
2. Arevalo JF, Maia M, Flynn HW Jr, et al., (2008): Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92: 213-216. (Pubitemid 351224097)
3. Avery RL, Pearlman J, Pieramici DJ, et al., (2006): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695-1705.
4. Bakri SJ, Snyder MR, Reid JM, Pulido JS, &, Singh RJ, (2007): Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859. (Pubitemid 46635858)
5. Barron H Genentech (2005): Important drug warning [letter]. US Food and Drug Administration Medwatch. Available at:. December 28.
6. Early Treatment Diabetic Retinopathy Group (1987): Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2. Ophthalmology 94: 761-774.
7. Fang X, Sakaguchi H, Gomi F, et al., (2008): Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86: 800-805.
8. Fong DS, Ferris FL III, Davis MD, &, Chew EY, (1999): Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 127: 137-141. (Pubitemid 29072552)
9. Hurwitz H, Fehrenbacher L, Novotny W, et al., (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
10. Jorge R, Costa RA, Calucci D, Cintra LP, &, Scott IU, (2006): Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26: 1006-1013. (Pubitemid 44973219)
11. Krohne TU, Eter N, Holz FG, &, Meyer CH, (2008): Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146: 508-512.
12. Mason JO III, Nixon PA, &, White MF, (2006): Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142: 685-688. (Pubitemid 44442055)
13. TM) injections. Acta Ophthalmol Scand 85: 689-691. (Pubitemid 47316777)
14. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, &, Balestrazzi E, (2008): Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 86: 683-687.
15. Rich RM, Rosenfeld PJ, Puliafito CA, et al., (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511. (Pubitemid 44620390)
16. Rodrigues EB, Shiroma H, Meyer CH, Maia M, &, Farah ME, (2007): Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 85: 915-916.
17. Rosenfeld PJ, Fung AE, &, Puliafito CA, (2005): Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36: 336-339. (Pubitemid 41073113)
18. Shima C, Sakaguchi H, Gomi F, et al., (2008): Complications in patients after intravitreal injection of Bevacizumab. Acta Ophthalmol 86: 372-376.
19. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, &, Adamis AP, (1996a): Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103: 1820-1828. (Pubitemid 26403735)
20. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, &, Adamis AP, (1996b): Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114: 964-970. (Pubitemid 26271462)
21. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, &, Jorge R, (2008): Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeH study). Acta Ophthalmol 86: 385-389.